• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human UPF0492 protein C20orf94 (C20orf94)

ACP16611

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP16611 Target NameSLX4IP
Target SynonymsbA204H22.1; bA254M13.1; C20orf94; Chromosome 20 open reading frame 94 ; CT094_HUMAN; dJ1099D15.3; RP5-1099D15.1; UPF0492 protein C20orf94FormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Expression Range1-408
Protein LengthFull length proteinPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ5VYV7
Background Information
  • Uniprot Id

    Q5VYV7

  • Target Species

    Human

  • Target Name

    SLX4IP

  • Target Full Name

    Protein SLX4IP

  • Target Involvement

    Chromosomal aberrations involving SLX4IP are found in acute lymphoblastic leukemia. A site-specific deletion within the 5' region of SLX4IP is found in 30% of childhood acute lymphoblastic leukemia in general and more than 60% of ETV6/RUNX1-rearranged acute lymphoblastic leukemia. Breakpoints within SLX4IP reveal junctions with typical characteristics of illegitimate V(D)J mediated recombination. SLX4IP deletions are significantly associated with male gender and ETV6/RUNX1-rearranged acute lymphoblastic leukemia.

  • Target Protein Families

    SLX4IP family

  • Target Synonyms

    bA204H22.1; bA254M13.1; C20orf94; Chromosome 20 open reading frame 94 ; CT094_HUMAN; dJ1099D15.3; RP5-1099D15.1; UPF0492 protein C20orf94

Inquire Recombinant Human UPF0492 protein C20orf94 (C20orf94) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification